[go: up one dir, main page]

PE20151654A1 - Inhibidores de cdc7 - Google Patents

Inhibidores de cdc7

Info

Publication number
PE20151654A1
PE20151654A1 PE2015001925A PE2015001925A PE20151654A1 PE 20151654 A1 PE20151654 A1 PE 20151654A1 PE 2015001925 A PE2015001925 A PE 2015001925A PE 2015001925 A PE2015001925 A PE 2015001925A PE 20151654 A1 PE20151654 A1 PE 20151654A1
Authority
PE
Peru
Prior art keywords
cdc7 inhibitors
cdc7
inhibitors
isoindolinone
cancer
Prior art date
Application number
PE2015001925A
Other languages
English (en)
Inventor
Robert Dean Dally
Timothy Andrew Woods
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PE20151654A1 publication Critical patent/PE20151654A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Epidemiology (AREA)

Abstract

La presente invencion se refiere a compuestos de 5 isoindolinona, o una sal del mismo farmaceuticamente aceptable, que inhiben CDC7 Y, por lo tanto pueden ser utiles en el tratamiento de cancer
PE2015001925A 2013-03-14 2014-03-07 Inhibidores de cdc7 PE20151654A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361782798P 2013-03-14 2013-03-14
US201361789108P 2013-03-15 2013-03-15

Publications (1)

Publication Number Publication Date
PE20151654A1 true PE20151654A1 (es) 2015-11-12

Family

ID=50382704

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2015001925A PE20151654A1 (es) 2013-03-14 2014-03-07 Inhibidores de cdc7

Country Status (36)

Country Link
US (1) US9156824B2 (es)
EP (1) EP2970221B1 (es)
JP (1) JP6064079B2 (es)
KR (1) KR101718645B1 (es)
CN (1) CN105008351B (es)
AP (1) AP2015008734A0 (es)
AU (1) AU2014228374B2 (es)
BR (1) BR112015020466B1 (es)
CA (1) CA2900773C (es)
CL (1) CL2015002530A1 (es)
CR (1) CR20150416A (es)
CY (1) CY1119199T1 (es)
DK (1) DK2970221T3 (es)
EA (1) EA027012B1 (es)
ES (1) ES2639793T3 (es)
GT (1) GT201500263A (es)
HR (1) HRP20171151T1 (es)
HU (1) HUE033482T2 (es)
IL (1) IL240962B (es)
JO (1) JO3383B1 (es)
LT (1) LT2970221T (es)
ME (1) ME02805B (es)
MX (1) MX363438B (es)
MY (1) MY188145A (es)
NZ (1) NZ710392A (es)
PE (1) PE20151654A1 (es)
PH (1) PH12015502091B1 (es)
PL (1) PL2970221T3 (es)
PT (1) PT2970221T (es)
RS (1) RS56122B1 (es)
SG (1) SG11201507541PA (es)
SI (1) SI2970221T1 (es)
TN (1) TN2015000349A1 (es)
TW (1) TWI622396B (es)
UA (1) UA116125C2 (es)
WO (1) WO2014143601A1 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013333534B2 (en) * 2012-10-15 2016-04-14 Pfizer Ireland Pharmaceuticals Process for the preparation of voriconazole and analogues thereof
ES2649156T3 (es) 2013-01-14 2018-01-10 Incyte Holdings Corporation Compuestos bicíclicos de carboxamida aromática útiles como inhibidores de quinasas Pim
EA035929B1 (ru) 2013-01-15 2020-09-02 Инсайт Холдингс Корпорейшн ТИАЗОЛКАРБОКСАМИДЫ И ПИРИДИНКАРБОКСАМИДЫ, ИСПОЛЬЗУЕМЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ Pim-КИНАЗЫ
JO3509B1 (ar) 2013-03-14 2020-07-05 Janssen Pharmaceutica Nv معدلات p2x7
WO2014152537A1 (en) 2013-03-14 2014-09-25 Janssen Pharmaceutica Nv P2x7 modulators
WO2014152589A1 (en) 2013-03-14 2014-09-25 Janssen Pharmaceutica Nv P2x7 modulators
AP2015008601A0 (en) 2013-03-14 2015-07-31 Boehringer Ingelheim Int Substituted 2-aza-bicyclo[2.2.1] heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin C
TWI599567B (zh) 2013-03-14 2017-09-21 健生藥品公司 P2x7調節劑
SG11201601259YA (en) 2013-08-23 2016-03-30 Incyte Corp Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors
US9822124B2 (en) 2014-07-14 2017-11-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
NZ728684A (en) 2014-09-12 2022-09-30 Boehringer Ingelheim Int Spirocyclic inhibitors of cathepsin c
EP3191488B1 (en) 2014-09-12 2019-08-14 Janssen Pharmaceutica NV P2x7 modulating n-acyl-triazolopyrazines
JP6592510B2 (ja) 2014-09-12 2019-10-16 ヤンセン ファーマシューティカ エヌ.ベー. P2x7調節因子
US9540347B2 (en) 2015-05-29 2017-01-10 Incyte Corporation Pyridineamine compounds useful as Pim kinase inhibitors
AR105967A1 (es) 2015-09-09 2017-11-29 Incyte Corp Sales de un inhibidor de pim quinasa
TW201718546A (zh) 2015-10-02 2017-06-01 英塞特公司 適用作pim激酶抑制劑之雜環化合物
WO2018055402A1 (en) * 2016-09-22 2018-03-29 Cancer Research Technology Limited Preparation and uses of pyrimidinone derivatives
AR113922A1 (es) 2017-12-08 2020-07-01 Incyte Corp Terapia de combinación de dosis baja para el tratamiento de neoplasias mieloproliferativas
CN108383771A (zh) * 2018-01-08 2018-08-10 华东师范大学 手性3,3-二取代异吲哚啉-1-酮衍生物及其合成方法和应用
GB201807147D0 (en) 2018-05-01 2018-06-13 Oncologica Uk Ltd Therapeutic combination
NL2021185B1 (en) 2018-06-26 2020-01-06 Stichting Het Nederlands Kanker Inst Antoni Van Leeuwenhoek Ziekenhuis Combination Therapy and Use Thereof for Treating Cancer
WO2020065614A1 (en) 2018-09-28 2020-04-02 Janssen Pharmaceutica Nv Monoacylglycerol lipase modulators
CR20210153A (es) 2018-09-28 2021-05-11 Janssen Pharmaceutica Nv Moduladores de monoacilglicerol lipasa
US20220220125A1 (en) * 2019-04-16 2022-07-14 Janssen Pharmaceutica Nv Fused isoindolin-1-one derivatives useful as grk2 inhibitors
CA3156100A1 (en) 2019-09-30 2021-04-08 Janssen Pharmaceutica Nv Radiolabelled mgl pet ligands
US11891387B2 (en) 2020-03-26 2024-02-06 Janssen Pharmaceutica Nv Monoacylglycerol lipase modulators

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0400970D0 (sv) * 2004-04-14 2004-04-14 Astrazeneca Ab Nicotinic acetylcholine receptor ligands
TW200639163A (en) * 2005-02-04 2006-11-16 Genentech Inc RAF inhibitor compounds and methods
US7576082B2 (en) * 2005-06-24 2009-08-18 Hoffman-La Roche Inc. Oxindole derivatives
CN101631546A (zh) * 2006-10-12 2010-01-20 泽农医药公司 螺-吲哚酮化合物作为治疗剂的用途
CN101790526A (zh) * 2007-06-08 2010-07-28 雅培制药有限公司 用作激酶抑制剂的5-杂芳基取代的吲唑化合物
US8648069B2 (en) 2007-06-08 2014-02-11 Abbvie Inc. 5-substituted indazoles as kinase inhibitors

Also Published As

Publication number Publication date
EP2970221A1 (en) 2016-01-20
AP2015008734A0 (en) 2015-09-30
BR112015020466A2 (pt) 2017-07-18
DK2970221T3 (en) 2017-07-31
US9156824B2 (en) 2015-10-13
CR20150416A (es) 2015-09-16
HUE033482T2 (en) 2017-12-28
EA201591509A1 (ru) 2015-12-30
KR20150119101A (ko) 2015-10-23
IL240962B (en) 2020-04-30
JP2016512498A (ja) 2016-04-28
TWI622396B (zh) 2018-05-01
HRP20171151T1 (hr) 2017-10-06
JP6064079B2 (ja) 2017-01-18
CN105008351B (zh) 2017-03-15
CA2900773C (en) 2018-04-17
CA2900773A1 (en) 2014-09-18
PH12015502091B1 (en) 2019-01-11
UA116125C2 (uk) 2018-02-12
PH12015502091A1 (en) 2016-01-18
TN2015000349A1 (en) 2017-01-03
HK1212696A1 (en) 2016-06-17
CL2015002530A1 (es) 2016-03-28
CN105008351A (zh) 2015-10-28
MY188145A (en) 2021-11-23
KR101718645B1 (ko) 2017-03-21
MX2015012583A (es) 2016-01-20
SG11201507541PA (en) 2015-10-29
ES2639793T3 (es) 2017-10-30
PL2970221T3 (pl) 2017-11-30
MX363438B (es) 2019-03-22
PT2970221T (pt) 2017-09-22
IL240962A0 (en) 2015-11-30
EP2970221B1 (en) 2017-06-28
SI2970221T1 (sl) 2017-08-31
NZ710392A (en) 2020-05-29
BR112015020466A8 (pt) 2019-11-12
RS56122B1 (sr) 2017-10-31
GT201500263A (es) 2016-03-02
EA027012B1 (ru) 2017-06-30
AU2014228374A1 (en) 2015-08-06
AU2014228374B2 (en) 2016-09-01
ME02805B (me) 2018-01-20
LT2970221T (lt) 2017-09-11
TW201521726A (zh) 2015-06-16
CY1119199T1 (el) 2018-02-14
JO3383B1 (ar) 2019-03-13
US20140275121A1 (en) 2014-09-18
BR112015020466B1 (pt) 2022-07-26
WO2014143601A1 (en) 2014-09-18

Similar Documents

Publication Publication Date Title
PE20151654A1 (es) Inhibidores de cdc7
CO2018013293A2 (es) Derivados de pirazolopirimidina como inhibidor de quinasa
ECSP17029203A (es) Inhibidor de cinasa aurora a
CL2019000844A1 (es) Compuesto de piridina.
MX2020004932A (es) Compuestos utiles para inhibir a cdk7.
AR110381A2 (es) Inhibidores biarilo de tirosina cinasa de bruton
JOP20190194A1 (ar) مركبات نيوكليوتيدات ثنائية حلقية لعلاج السرطان
ECSP14017584A (es) Compuestos inhibidores de raf
CR20150078A (es) Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn
ES2721001T3 (es) Derivado de isoindolina, y composiciones y métodos para tratar una enfermedad neurodegenerativa
PA8850801A1 (es) Compuestos útiles para inhibir chk1
CO2020007156A2 (es) Derivado de amino-metil piperidina como inhibidor de quinasa
CL2016002971A1 (es) Combinación.
MX2015006039A (es) Derivados de pirimidin-2, 4-diamina para el tratamiento de cancer.
UY36075A (es) Derivados de tubulisina
CR20140036A (es) Compuesto inhibidor de la señalización de la trayectoria notch
BR112017000730A2 (pt) derivados de pirrolidinona como inibidores de metap-2
DOP2019000194A (es) Derivados de pirrolotriazina como inhibidor de cinasas
PE20151587A1 (es) Composicion farmaceutica que comprende al 3-carboxi-n-etil-n,n-dimetilpropein-1-aminio o una sal farmaceuticamente aceptable del mismo

Legal Events

Date Code Title Description
FG Grant, registration